Bruker Corporation · NASDAQ:BRKR
Bruker — Q3 2025 Earnings Presentation
17 slides from Bruker's earnings presentation, Nov 3, 2025
Slide 1: Q3 2025 Earnings Presentation
BRUKER CORPORATION (NASDAQ: BRKR) Q3 2025 Earnings Presentation November 3, 2025 Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations
Slide 2: Safe Harbor Statement
BRUKER CORP ORATI ON Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 193
Slide 3: Business Update
Q3 2025 Business Update 3
Slide 4: Q3 2025: Organic revenue, non-GAAP operating margin, and EPS decline
Q3 2025: Organic revenue, non-GAAP operating margin, and EPS decline on research instrument demand headwinds in H1-25 Q3 2025 Performance; Year-over-Year Changes Q3 Financials Revenues [$M] ❖ Revenue decrease of -$3.9M, or -0.5% ▪ Organic decline -4.5%, with BSI -5.4%, and BEST up +6.9% 860.5 864.4
Slide 5: Q3-25 YTD: Revenue growth driven by M&A; margin and EPS down
Q3-25 YTD: Revenue growth driven by M&A; non-GAAP operating margin and EPS down on YTD demand, tariff and FX headwinds Q3 2025 YTD Performance; Year-over-Year Changes Q3-YTD Financials Revenues [$M] ❖ Revenue increase of $72.5M, or 3.0% 2459.3 ▪ Organic revenue down -3.1%, with BSI down -2.9%, BEST
Slide 6: Bruker Group YTD CER Revenue Performance (yoy)
GROUP OVERVIEW Bruker Group YTD CER Revenue Performance (yoy) Bruker BIOSPIN Group ▪ BIOSPIN YTD CER revenue down mid-single digits % ▪ Growth from lab automation and services ▪ Challenging Q3-25 comparison with two GHz-class NMRs (>$25m) in Q3-24 revenue Bruker CALID Group ▪ CALID YTD CER revenue u
Slide 7: Bruker Group YTD CER Revenue Performance (yoy)
GROUP OVERVIEW Bruker Group YTD CER Revenue Performance (yoy) Bruker NANO Group ▪ NANO YTD CER revenue down low single digits % ▪ Softness in X-Ray Semi and NanoAnalysis industrial research tools ▪ Solid growth in Spatial Biology, including NanoString ▪ Strengthening industrial and applied markets i
Slide 8: Recent NIH- and NSF-funded Orders for Advanced NMR Instruments
US A C A D E M I C O R D E R E X A M P L E S I N Q 3 - 2 5 Recent NIH- and NSF-funded Orders for Advanced NMR Instruments ▪ Enabling breakthroughs across scientific research, drug discovery and disease biology research ▪ Aggregate value of ~$10M, expected to be installed in 2026 ▪ BSI ACA/GOV orders
Slide 9: Recent Multi-Year Contracts for Explosives and Chemical Trace Detection
CBRNE DETECTI ON Recent Multi-Year Contracts for Explosives and Chemical Trace Detection in Aviation Security and Defense Sectors Bruker Detection provides solutions for airline safety, airport passenger and cargo security, and chemical reconnaissance, including after-market consumables and service
Slide 10: Financial Update
Q3 2025 Financial Update 10
Slide 11: Q3 2025 Selected Non-GAAP Financial Measures
Q3 2025 YEAR-OVER-YEAR COMPARISON Q3 2025 Selected Non-GAAP Financial Measures1 [$ m, except EPS] Q3 2025 Q3 2024 Δ Comments (year-over-year) Total Revenues 860.5 864.4 (0.5%) ▪ Revenue decline of -0.5% Gross Profit 430.9 442.2 (2.6%) Margin (% of revenues) 50.1% 51.2% -110 bps ▪ BSI organic revenue
Slide 12: Q3-25 YTD Selected Non-GAAP Financial Measures
YTD 2025 YEAR-OVER-YEAR COMPARISON Q3-25 YTD Selected Non-GAAP Financial Measures1 [$ m, except EPS] YTD 2025 YTD 2024 Δ Comments (year-over-year) Total Revenues 2,459.3 2,386.8 3.0% ▪ Revenue growth of 3.0% Gross Profit 1,229.0 1,222.7 0.5% Margin (% of revenues) 50.0% 51.2% -120 bps ▪ BSI organic
Slide 13: YTD Q3 2025 Selected Cash Flow And Balance Sheet Measures
YTD 2025 YEAR-OVER-YEAR COMPARISON YTD Q3 2025 Selected Cash Flow And Balance Sheet Measures [$M] YTD 2025 YTD 2024 Δ Comments (year-over-year) GAAP Net Income (37.5) 99.9 (137.4) Depreciation & amortization 162.2 130.9 31.3 ▪ Free cash flow down -$146.6M, impacted by: Changes in working capital (79
Slide 14: Updated FY 2025 Outlook
CEQ) So ad - Updated FY 2025 Outlook
Slide 15: Updated FY 2025 Financial Outlook (as of November 3, 2025)
Updated FY 2025 Financial Outlook (as of November 3 , 2025) rd Non-GAAP Assumptions & YoY Estimates FY 2025 Guidance (year-over-year %s) ▪ FY25 operating margin down ~250 bps Revenue $3.41B to $3.44B ▪ Organic -65bps; M&A -60bps; Tariffs -60bps; FX -65bps Reported Revenue Growth +1% to +2% ▪ FX impa
Slide 16: Supplementary Financial Information
Supplementary Financial Information* * - For preliminary financial statements, GAAP to Non-GAAP reconciliations, and other supplementary financial information, please refer to our Q3 2025 Earnings Press Release issued November 3rd, 2025. 16
Slide 17: ;
;